Scheduled to become operational this quarter, the logistics hub will provide full cGMP-compliant storage and distribution services and will serve as a clinical supply depot. This expansion will support CollPlant's growing customer base for its rhCollagen and BioInk product lines in both the U.S. and Canada.
The new U.S. logistics center features state-of-the-art infrastructure, including cGMP-controlled storage environments, a cloud-based temperature monitoring system, advanced emergency back-up capabilities, AI-powered security, and remote inventory management. These capabilities ensure reliable, efficient, and secure distribution to meet the quality and regulatory expectations of CollPlant's partners and customers.
Yehiel Tal, CollPlant's Chief Executive Officer commented, "The establishment of a U.S. logistics center demonstrates our long-term commitment to the North American market and represents an important milestone in advancing regenerative medicine products based on our rhCollagen technology.
This center is expected to increase efficiency and reduce shipping time, ensuring our customers experience uninterrupted access to our products. By maintaining local inventory, we are strengthening our ability to rapidly support customer needs and scale with market demand."
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications within the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information please, visit http://www.collplant.com.
